<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Proliferating and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells express the glycolytic isoenzyme, <z:chebi fb="1" ids="15361">pyruvate</z:chebi> kinase type M2 (M2-PK) </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> cells, M2-PK usually exists in dimeric form (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> M2-PK), causing the accumulation of glycolytic phosphometabolites, which allows cells to invade areas with low oxygen and <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations </plain></SENT>
<SENT sid="2" pm="."><plain>AIMS: To investigate the expression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> M2-PK during the <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, and to assess the prognostic usefulness of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> M2-PK in <z:e sem="disease" ids="C0546837" disease_type="Neoplastic Process" abbrv="">oesophageal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS/METHODS: One hundred and ninety cases selected from the histopathology archives as follows: 17 reflux <z:e sem="disease" ids="C0014868" disease_type="Disease or Syndrome" abbrv="">oesophagitis</z:e>, 37 Barrett's oesophagus, 21 high grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 112 <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, and three control <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Sections were stained immunohistochemically with antibody to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> M2-PK </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> M2-PK was expressed in <z:hpo ids='HP_0000001'>all</z:hpo> cases, and increased cytoplasmic expression was seen with progression along the <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> showed 100% staining so that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> M2-PK was not a useful prognostic marker </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> M2-PK is not a specific marker of Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, but may be important as a marker of transformed and highly proliferating clones during progression along the <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence </plain></SENT>
</text></document>